CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer.

Bugide, Suresh; Edwards, Yvonne J K; Gupta, Romi; Green, Michael R; Wajapeyee, Narendra

Bugide, Suresh; Edwards, Yvonne J K; Gupta, Romi; Green, Michael R; Wajapeyee, Narendra.

Afiliação

Bugide S; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35222.
Edwards YJK; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35222.
Gupta R; Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35222.
Green MR; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35222.
Wajapeyee N; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605.

Proc Natl Acad Sci U S A ; 120(4): e2218118120, 2023 01 24.

Article em En | MEDLINE | ID: mdl-36652476

Assuntos

Adenocarcinoma de Pulmão; Neoplasias Pulmonares; Humanos; Animais; Camundongos; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patologia; Receptores ErbB/metabolismo; Adenocarcinoma de Pulmão/tratamento farmacológico; Adenocarcinoma de Pulmão/genética; Adenocarcinoma de Pulmão/patologia; RNA Interferente Pequeno/genética; RNA Interferente Pequeno/uso terapêutico; Resistencia a Medicamentos Antineoplásicos/genética; Linhagem Celular Tumoral

Palavras-chave

EGFR; drug resistance; epigenetics; lung cancer; transcription regulation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma de Pulmão / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google